EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521

Bin-Chi Liao iD, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo iD, Inn-Wen Chong iD, Tsung-Ying Yang, Chun-Liang Lai iD, Te-Chun Hsia, Ching-Liang Ho iD, Kang-Yun Lee, Chin-Fu Hsiao und 3 weitere

JCO Global Oncology · 2024

DOI: 10.1200/go.24.00125 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Bin-Chi Liao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, High-Throughput Nucleotide Sequencing, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non–small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS analysis. MATERIALS AND METHODS We enrolled 500 patients with advanced/metastatic (1) epidermal growth factor receptor ( EGFR ) mutations or anaplastic large-cell lymphoma kinase ( ALK ) rearrangement–positive NSCLC who had failed at minimum one line of tyrosine kinase inhibitor (TKI) therapy, (2) EGFR-/ALK -negative nonsquamous, and (3) non- or light-smoker patients with squamous NSCLC who were treatment-naïve or had failed at maximum two lines of systemic treatment. These patients were divided into five cohorts. Comprehensive tissue-based NGS testing (ACTOnco+) was conducted. RESULTS Cohort 1: EGFR TKI-pretreated EGFR -mutated population (50.0%, n = 250), cohort 2: ALK inhibitor-pretreated ALK -positive population (1.6%, n = 8), cohort 3: treatment-naïve EGFR-/ALK -negative population (28.2%, n = 141), cohort 4: pretreated EGFR-/ALK -negative population (16.8%, n = 84), and cohort 5: squamous cell carcinoma (3.4%, n = 17). In cohort 1, 11.2% (28/250) of the patients had MET amplification, 32.4% (81/250) had been treated with osimertinib, and EGFR C797S was detected in 6.2% (5/81) of these patients. In cohort 2, resistance ALK mutation was detected in 37.5% (3/8) of the patients. In cohorts 3 and 4, targetable genetic alterations, including EGFR mutation (13.3%), ERBB2 mutation (9.3%), MET exon 14 skipping (5.3%), KRAS G12C mutation (4.4%), ROS1 fusion (2.7%), RET fusion (1.8%), and BRAF V600E mutation (1.3%), were detected. In cohort 5, MET exon 14 skipping was detected in 29.4% (5/17) of the patients. CONCLUSION This multicenter registration study investigated tissue-based NGS for a specific patient population with NSCLC in Taiwan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingLung NeoplasmsMutationHumansMaleFemaleMiddle AgedTaiwanAgedCohort StudiesAdultRegistriesErbB ReceptorsAged, 80 and overProtein Kinase InhibitorsAnaplastic Lymphoma Kinase

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAnaplastic Lymphoma Kinase

Autor:innen und Institutionen

  • Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.

ORCID-Profile: Bin-Chi Liao, Yung-Hung Luo, Inn-Wen Chong, Chun-Liang Lai, Ching-Liang Ho, Wei-Tse Fang, James Chih-Hsin Yang

Zitieren

APA

Liao, B. C., Chiang, N. J., Chang, G. C., Su, W. C., Luo, Y. H., Chong, I. W., Yang, T. Y., Lai, C. L., Hsia, T. C., Ho, C. L., Lee, K. Y., Hsiao, C. F., Ku, F. C., Fang, W. T., & Chih-Hsin Yang, J. (2024). Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521. JCO Global Oncology. https://doi.org/10.1200/go.24.00125

Vancouver

Liao BC, Chiang NJ, Chang GC, Su WC, Luo YH, Chong IW, et al. Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521. JCO Global Oncology. 2024. doi:10.1200/go.24.00125

BibTeX
@article{Liao2024,
  author = {Liao, Bin-Chi and Chiang, Nai-Jung and Chang, Gee-Chen and Su, Wu-Chou and Luo, Yung-Hung and Chong, Inn-Wen and Yang, Tsung-Ying and Lai, Chun-Liang and Hsia, Te-Chun and Ho, Ching-Liang and Lee, Kang-Yun and Hsiao, Chin-Fu and Ku, Fan-Chen and Fang, Wei-Tse and Chih-Hsin Yang, James},
  title = {Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.24.00125}
}
Kostenlos starten →